RGBP just crossed over resistance, retested and continued uptrend setting up for long trade with stop loss below the horizontal line. Presently up 70% since 7/27 earnings Crossing EMA Ribbon shows divergence /momentum
Considering a $5 Strike for Jan. '23
Trade active
⋅
Appears to be ready to move higher after a pullback
@Alzasa0f1, I only see a long; the first target is 0.0099 while the second is 0.0118 based on the volume profile; today was all Doji candles in a consolidation. Yesterday was a downtrend into the consolidation. I see an uptrend out of the consolidation. I suppose a good entry is 0.0002 above the upcoming premarket's high.
Alzasa0f1
⋅
Thank you 🙏
Alzasa0f1
⋅
But what about long term ?
AwesomeAvani
⋅
@Alzasa0f1, This is a biotech penny stock take it for what it is. Long term is speculation in this. That said, there was a recent catalyst, an FDA filing. See barchart.com/story/news/9332899/regen-biopharma-inc-files-provisional-patent-application-on-second-generation-survivin-mrna-cancer-immunotherapy-vaccine (clip and paste the URL) If this hits, the penny stock goes up at least 20X and if it does not maybe goes down 75%- meets and exceeds the speculationdefinition. It is OTC because the current financials and fundamentals do not permit listing on the big board. So it is priced for potentials only and FDA controls the potentials. It is kind of buying vaccine stocks before COVID hit knowing that COVID was coming ( yes, there are some who knew ahead of time). That said, I am a retired physician and biomedical engineer. I have a special interest in the biotech sector. Does any of this make sense?
Alzasa0f1
⋅
The merge is coming
AwesomeAvani
⋅
@Alzasa0f1, I do not know anything about a merger. There was a patent filing which caused the price action. This is now over bought. The next move is a pullback correction and a buying opportunity when that dip occurs. SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company's novel approach for enabling chimeric antigen receptor (CAR)-T cell-based therapies to kill solid tumors through prevention of a process called "T cell exhaustion".